Combination | Jotup

KEON CAPITAL INC. EXECUTES DEFINITIVE AGREEMENTS RESPECTING PROPOSED TRANSACTION WITH FRAME HOLDINGS INC.

Retrieved on:

Wednesday, March 13, 2024

Combination, TSX Venture Exchange, Private, Minority, News, Business analyst, Multilateral, Transaction, Policy, Security (finance)

Vancouver, B.C., March 13, 2024 (GLOBE NEWSWIRE) -- Keon Capital Inc. (“Keon” or the “Company”) (TSXV: KEON.H) is pleased to provide an update respecting its previously announced transaction (the “Transaction”) with Frame Holdings Inc. (“Frame”) pursuant to which Keon will acquire all of the issued and outstanding Frame shares from the Frame shareholders (see Keon’s news release dated November 6, 2023 announcing the execution of an LOI respecting the Transaction).

Key Points:

Vancouver, B.C., March 13, 2024 (GLOBE NEWSWIRE) -- Keon Capital Inc. (“Keon” or the “Company”) (TSXV: KEON.H) is pleased to provide an update respecting its previously announced transaction (the “Transaction”) with Frame Holdings Inc. (“Frame”) pursuant to which Keon will acquire all of the issued and outstanding Frame shares from the Frame shareholders (see Keon’s news release dated November 6, 2023 announcing the execution of an LOI respecting the Transaction).
The Transaction is structured as a three-cornered amalgamation (the “Amalgamation”), with Frame amalgamating with Subco and becoming a wholly-owned subsidiary of Keon.
Shareholders of Frame will receive one common share in the capital of Keon in exchange for each outstanding common share of Frame held by them, with Keon expected to issue an aggregate of approximately 40,000,000 Keon shares (assuming the minimum Frame financing of $2,000,000) to the Frame shareholders under the Transaction.
In connection with the Transaction, Keon will conduct a 2.8:1 share consolidation of issued and outstanding Keon common shares (the “Keon Share Consolidation”), and any shares issued to Frame shareholders under the Transaction will be on a post-consolidation basis.

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Retrieved on:

Tuesday, March 12, 2024

Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Merck, Cancer, Pembrolizumab, Lung cancer, DLT, Merck & Co., Kineta, NK, Pharmaceutical industry

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as monotherapy and in combination with Merck’s anti-PD therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.

Key Points:

KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
We continue to be encouraged by the safety profile of KVA12123, supporting advancement to higher doses,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

Retrieved on:

Tuesday, April 2, 2024

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.

Key Points:

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.
Thousands of industry representatives, regulators, government officials, academics, innovators, and patients will convene for the world's preeminent neutral life sciences forum — and the only thing missing is you.
"This year marks the 60th anniversary of DIA and the Global Annual Meeting, and we're celebrating by continuing to forge a bold future marked by innovation and impact," said Marwan Fathallah, DIA's President and Global Chief Executive.
— An interactive forum featuring U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) representatives discussing today's regulatory, scientific, and communication challenges.

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on:

Tuesday, March 26, 2024

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points:

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
“Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

New Renesas MCUs with High-Resolution Analog and Over-the-Air Update Support Help Customer Systems Conserve Energy

Retrieved on:

Thursday, March 21, 2024

RA2A2 MCUs contribute to the digitalization of conventional systems with key features including high-level analog sensing, FOTA support, 8KHz/4KHz hybrid sampling, and AES hardware accelerator functions.

Key Points:

RA2A2 MCUs contribute to the digitalization of conventional systems with key features including high-level analog sensing, FOTA support, 8KHz/4KHz hybrid sampling, and AES hardware accelerator functions.
When the end-systems are digitalized, it is possible to analyze individual systems status seamlessly for further energy-efficient, streamlining system operation.
The adoption of smart meters with NILM is the most cost-effective and scalable solution for increasing energy efficiency and lowering energy consumption.
“Renesas has worked closely with our customers to understand their requirements for next-generation systems that can support critical energy conservation goals,” said Akihiro Kuroda, Vice President of the Embedded Processing 2nd Division at Renesas.

UL Solutions Warns of Unauthorized UL Marks on Combination CO & Smoke Alarms

Retrieved on:

Friday, March 29, 2024

Smoke, Carbon, UL, Combination, Walmart, Electronics, Safety, Phosphorus

NORTHBROOK, Ill., March 29, 2024 /PRNewswire/ -- The following is a notification from UL Solutions that the Combination CO & Smoke Alarms identified below bear unauthorized UL Certification Marks for the United States and Canada.

Key Points:

NORTHBROOK, Ill., March 29, 2024 /PRNewswire/ -- The following is a notification from UL Solutions that the Combination CO & Smoke Alarms identified below bear unauthorized UL Certification Marks for the United States and Canada.
The Combination CO & Smoke Alarms have not been evaluated by UL Solutions to the appropriate Safety Standards, and it is unknown if the Combination CO & Smoke Alarms comply with any safety requirements.
Remedy: UL Solutions recommends that these products be removed from service and be replaced by a UL Certified Carbon Monoxide CO & Smoke Alarm.
Identification on the Product: The Combination CO & Smoke Alarms bear unauthorized UL Certification Marks for the United States and Canada and the following:
Location: Known to be distributed and sold by Shenzhen Cordier Electronics Ltd and Dongguan Gongxian Electronics Co. Ltd. and have been sold through e-commerce retailers, including Walmart.com.

Edoc Acquisition Corp. Announces Postponement of Special Meeting of Shareholders on Proposed Business Combination

Retrieved on:

Tuesday, February 27, 2024

ACN, Proxy, Telephone, Meeting, Combination, AOI, ADOC, Business, Business analyst, Eastern Time Zone, Physician, Sub

Victor, NY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the “Meeting”) to approve its proposed initial business combination, which was re-scheduled from February 26, 2024 to February 28, 2024, has been further postponed to 4:30p.m.

Key Points:

Victor, NY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the “Meeting”) to approve its proposed initial business combination, which was re-scheduled from February 26, 2024 to February 28, 2024, has been further postponed to 4:30p.m.
There is no change to the location, the record date, the purpose or any of the proposals to be acted upon at the Meeting.
The reason for the postponement is that AOI is engaged in additional negotiations regarding potential financing to occur in connection with the closing of the Proposed Business Combination.
The record date for holders of EDOC’s shareholders for voting in the Meeting remains February 2, 2024 (the “Record Date”).

Edoc Acquisition Corp. Announces Postponement of Special Meeting of Stockholders on Proposed Business Combination

Retrieved on:

Friday, February 23, 2024

ACN, Proxy, Telephone, Meeting, Combination, AOI, ADOC, Business, Business analyst, Physician, Sub

Victor, NY, Feb. 23, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the “Meeting”) to approve its proposed initial business combination, which was scheduled for February 26, 2024, has been postponed to 10:00 a.m. Eastern Time, on Wednesday, February 28, 2024.

Key Points:

Victor, NY, Feb. 23, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the “Meeting”) to approve its proposed initial business combination, which was scheduled for February 26, 2024, has been postponed to 10:00 a.m. Eastern Time, on Wednesday, February 28, 2024.
There is no change to the location, the record date, the purpose or any of the proposals to be acted upon at the Meeting.
The reason for the postponement is that AOI is engaged in additional negotiations regarding potential financing to occur in connection with the closing of the Proposed Business Combination.
The record date for holders of EDOC’s shareholders for voting in the Meeting remains February 2, 2024 (the “Record Date”).

SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders

Retrieved on:

Thursday, February 22, 2024

Plan, Special, FDA, Combination, EDEN, Business analyst, Security (finance), Link, The Company, Agreement

EDEN PRAIRIE, MN, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the result of its special meeting (the “Special Meeting”) to approve its business combination with SEP Acquisition Corp. The results, as reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 21, 2024 (Link), were as follows:

Key Points:

At a special meeting of stockholders on February 21, 2024, SANUWAVE stockholders approved the business combination with SEP Acquisition Corp. by a vote of 798,379,869 “for” and 5,221,765 “against” with 71,525 abstaining
EDEN PRAIRIE, MN, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the result of its special meeting (the “Special Meeting”) to approve its business combination with SEP Acquisition Corp.
Both proposals were approved, each receiving the affirmative requisite vote of the holders of shares of the Company’s common stock.
Although Proposal 2 was approved, the adjournment of the Special Meeting to solicit additional proxies was not necessary because there were sufficient votes at the time of the Special Meeting to adopt Proposal 1.
Each proposal is described in detail in the Company’s definitive proxy statement filed with the SEC on January 22, 2024.

Broad Capital Acquisition Corp Confirms Funding to Extend Period to Consummate Initial Business Combination to March 13, 2024

Retrieved on:

Wednesday, February 21, 2024

Acquisition, Combination, BRAC

Dallas, Texas, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on February 12, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to March 13, 2024 (the “Monthly Extension”).

Key Points:

Dallas, Texas, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on February 12, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to March 13, 2024 (the “Monthly Extension”).
The Monthly Extension is the second of the twelve monthly extensions permitted under the Company’s Amended and Restated Certificate of Incorporation, as amended to date.
On January 18, 2023, the Company entered into a definitive Agreement and Plan of Merger and Business Combination Agreement, as amended (the “Business Combination Agreement”), with Openmarkets Group Pty Ltd, an Australian proprietary limited company (“OMG”), BMYG OMG Pty Ltd, an Australian proprietary limited company, and Broad Capital LLC, a Delaware limited liability company, solely in its capacity as the Company’s sponsor, pursuant to which the Company will enact its initial business combination.